

Psinuvia Incorporated

Company Overview

Psinuvia Incorporated was founded in 1995 by two former scientists and medical diagnostic and treatment system specialists from the National Institutes of Health (NIH). Their goal in creating Psinuvia Inc. was to bring leading-edge medical diagnostic and treatment system (MDTS) technologies to market quickly and efficiently.

The company's first advancements centered on the creation of more efficient and effective heart defibrillation and resynchronization (pacemaker) technologies. The organization has successfully modernized the pacemaker/defibrillator machine. To a large extent, today's Wi-Fi and wireless systems have been blended with patient devices. This combination enables faster and more effective treatment and tracking of a number of different cardiac diagnoses and treatment regimens. Within this segment of the MDTS market, Psinuvia Inc. is unchallenged with regards to both market share and profitability.

The latest area of endeavor for Psinuvia Inc. involves the monitoring and reporting of overall health statistics and blood count levels for high-risk patients. The current research has shown that a more persistent monitoring regimen, along with a structured accountability program, has a significant impact on overall health. This finding is especially true when describing those abusing either prescription or recreational drugs. Psinuvia Inc. is the first to combine quick and painless assessment methodologies along with online and wireless reporting capabilities. This combination has given medical, legal, and law enforcement personnel an efficient and effective way to monitor patient progress without a significant time commitment from the patient.

At present, Psinuvia Inc. employs approximately 500 people across the United States, Canada, and Singapore in manufacturing and research facilities. Psinuvia Inc.'s internal projections estimate a need to increase its employees to approximately 750 by the end of 2018 and to close to 1,000 by 2020. Annual sales in 2017 amounted to nearly \$700 million.